新股消息 | 泰励生物递表港交所 专注于发现与开发创新肿瘤疗法

Company Overview - Tyligand Bioscience, established in 2017, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies. The drug portfolio includes four candidate drugs, with the core product TSN1611 being a selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China, aimed at treating non-small cell lung cancer (NSCLC) [3][6]. Financial Information - The company reported revenues of RMB 7.856 million for the fiscal year 2024, RMB 1.506 million for the nine months ending September 30, 2024, and RMB 11.358 million for the nine months ending September 30, 2025 [5][6]. - The company incurred losses of approximately RMB 70.461 million for the fiscal year 2024, RMB 28.354 million for the nine months ending September 30, 2024, and RMB 123.406 million for the nine months ending September 30, 2025 [7]. - Gross profits were reported as RMB 7.121 million for the fiscal year 2024, RMB 1.506 million for the nine months ending September 30, 2024, and RMB 8.894 million for the nine months ending September 30, 2025 [8]. Industry Overview - Cancer is a leading cause of death globally, with approximately 10 million deaths annually. In 2024, there are expected to be 21.3 million new cancer cases, projected to rise to 27.1 million by 2035. In China, the most prevalent cancers are lung, colorectal, and thyroid cancers [9]. - The global oncology drug market has expanded significantly, with a market size growing from USD 150.3 billion in 2020 to USD 253.3 billion in 2024, reflecting a compound annual growth rate (CAGR) of 13.9%. It is expected to reach USD 702.7 billion by 2035, with immunotherapy being a major growth driver [9]. - The Chinese oncology drug market has also seen rapid growth, increasing from RMB 197.5 billion in 2020 to RMB 258.2 billion in 2024, with a CAGR of 6.9%. It is projected to reach RMB 1.04 trillion by 2035, with immuno-oncology drugs expected to capture a significant market share [12].